Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
OPERATING ACTIVITIES    
Net (loss) income $ (89) $ 1,033
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Provision for doubtful accounts (84) (99)
Depreciation 8,131 7,705
Loss on disposal of and reserve adjustments for medical equipment 1,450 848
Gain on sale of medical equipment (1,348) (1,588)
Amortization of intangible assets 2,125 3,264
Amortization of deferred debt issuance costs 55 132
Stock-based compensation 3,236 4,962
Deferred income taxes (331) (875)
Changes in assets - (increase)/decrease:    
Accounts receivable (607) 217
Inventories (922) (630)
Other current assets 224 251
Other assets (89) (102)
Changes in liabilities - increase/(decrease):    
Accounts payable and other liabilities 1,200 (513)
NET CASH PROVIDED BY OPERATING ACTIVITIES 12,951 14,605
INVESTING ACTIVITIES    
Acquisition of business 0 (7,650)
Purchase of medical equipment (10,452) (9,645)
Purchase of property and equipment (571) (607)
Proceeds from sale of medical equipment, property and equipment 2,597 2,214
NET CASH USED IN INVESTING ACTIVITIES (8,426) (15,688)
FINANCING ACTIVITIES    
Principal payments on long-term debt (31,089) (69,306)
Cash proceeds from long-term debt 32,398 61,654
Debt issuance costs 0 (386)
Cash payment of contingent consideration (750) 0
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (698) (1,141)
Common stock repurchased as part of share repurchase program (5,359) 0
Cash proceeds from stock plans 1,150 779
NET CASH USED IN FINANCING ACTIVITIES (4,348) (8,400)
Net change in cash and cash equivalents 177 (9,483)
Cash and cash equivalents, beginning of period 186 9,648
Cash and cash equivalents, end of period $ 363 $ 165